Investing in Capsulution

Capsulution is one of the leading international nanotechnology companies. Already in 2004 the magazine M.I.T – Technology Review named our company as one of the world’s foremost providers of nanotechnology and high-value products in the Life Science field.

The technology platform we developed at the Max-Planck Institute of Colloids and Interfaces in the 1990s gives us a solid foundation for numerous innovative products, including the targeted delivery of medication and non-invasive blood glucose measurement, which we license to some of the most well-known companies in the pharmaceutical industry.

These successes are among the reasons the respected market research agency Frost & Sullivan gave us the 2005 „Product Differentiation Innovation Award“ in the worldwide market for nanobiotechnology.

Already in its first few years Capsulution achieved significant revenues, and since then has always—in contrast to many newer companies in the field—reached its rapidly rising financial targets. Capsulution has already signed long-term development contracts whose royalty income can be expected to reach 50 million euros in the next few years.

The number of products in our development pipeline has grown again in recent months. By working for a wide number of clients in the Life Science field we are spreading our risk and profiting from synergies between individual product specifications.

The growing success of Capsulution gives investors and shareholders the opportunity to profit from rapid investment value growth in a short period of time.

We invite you to learn more about Capsulution. We would be happy to provide you with any additional information you need about the successful future of our company.